Скачать или смотреть Divis Labs- Q2FY26 Earnings Insights

🚀 Divis Laboratories Q2 FY26 Earnings: Power-Packed Growth Unlocked! 📈💥

💊 "Pharma powerhouse Divis Labs flexes strong gains: +35% PAT & soaring revenue! 💰📈"

🔥 Key Highlights You Can’t Miss:
📊 Revenue: ₹2,860 Cr | +17% YoY 📅 +13% QoQ ↗️
💰 PAT: ₹689 Cr | +35% YoY 🌟 +26% QoQ 🚀
📈 EBITDA Margin: Expands to ~36% | Strong operational efficiency ✔️
🤑 EPS: ₹25.97 | Up 35% YoY
🌍 Forex Gains: ₹63 Cr - More than doubled vs last year 💸

🔑 Growth Drivers at Play:
✨Dominating in custom synthesis & intermediates, now over 50% of business 🔬
✨Nutra division expanding with fresh leadership - new horizons ahead 🌱
✨Steady investments in R&D & capacity fueling innovation 🇮🇳

💡 Expense Insights:
⚡Expenses grew slower than revenue = margin expansion 💪
⚡Optimal cost controls + operational efficiencies shining through ✨
⚡Forex gains acting as a sweet profit booster 💹

💬 Management Talk:
“Stable generics volumes & strong innovation pipelines will keep our growth engine roaring. Peptide center of excellence & focused CapEx initiatives set us apart from competition.” - Divis leadership

🌟 Outlook:
With a robust order book and strategic R&D focus, Divis Laboratories is gearing up for a resilient, profitable future. Expect continued growth momentum and margin expansion as they build on strong fundamentals! 🚀📊

#DivisLaboratories #IndianPharma #PharmaLife #APIs #StockMarketIndia #Divis #Pharma #PharmaIndustry #ActivePharmaceuticalIngredients #Nutraceuticals #API #pharmaceuticals #Q2FY26results #q2results #Q2Earnings #Earnings #Results #Q2FY26 @ZinvestZ #ZinvestZ #divislabs 🚀

🔔 Follow @zinvestz for more powerful investing stories & deep-dive analyses! ) 💼 📊

(Disclaimer: This post is for informational purposes only. DYOR before investing! 📈)